Second Contagious Cancer Found in Tasmanian Devils

A second fatal, transmissible cancer has been identified in the already endangered species.

Written byAnna Azvolinsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Tasmanian devilWIKICOMMONS, KERESHDevil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii) was first found in 1996. Ten years later, it was confirmed as a transmissible cancer. The disease spreads from animal to animal via living cancer cells, causing tumors on the side of the faces or inside the mouths of the carnivorous marsupials. Now, researchers have found a second such tumor, one that is genetically and histologically distinct from DFTD in five animals. The analysis of this new transmissible tumor, called DFT2, appeared this week (December 28) in PNAS.

DFTD, which researchers are now calling DFT1, was first noticed by a wildlife photographer and traced by researchers to a female animal. Biting spreads the tumors, which arose from mutated neural support cells called Schwann cells. The tumors metastasize readily to the lymph nodes, lungs, and kidneys in the animals. Transmissible cancers are very rare, although not all are fatal. So far, such tumors have been found in only three species—dogs, Tasmanian devils, and soft-shell clams.

“The devils and their tumors have been closely monitored since discovery of DFT1 and DFT2 was detected as a result of this close monitoring,” study coauthor Ruth Pye of the University of Tasmania’s Menzies Institute for Medical Research wrote in an email to The Scientist.

“One transmissible cancer is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies